Phase 3 trial of pacritinib in myelofibrosis patients with severe thrombocytopenia
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis; Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Acronyms PACIFICA
- Sponsors CTI BioPharma
- 18 Jul 2019 According to a CTI BioPharma media release, Professor Claire Harrison, Professor of Medicine, Guy's and St Thomas' NHS Foundation Trust, London, will chair the study's Steering Committee.
- 18 Jul 2019 According to a CTI BioPharma media release, Dr. Srdam Verstovsek, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and Dr. John Mascarenhas, Associate Professor of Medicine Myeloproliferative Disorders Program, Tisch Cancer Institute, Mount Sinai School of Medicine, will be co-principal investigators in the study.
- 18 Jul 2019 According to a CTI BioPharma media release, the company expects to report topline data from the study in mid-2021.